CD4 and cancer: Among the HDAC inhibitors we tested, Belinostat, Romidepsin (HDAC1 and 2), and Tubastatin (HDAC6) inhibited acetylation at H3 and H4 using cancer cells but did not affect the ability of Mtb-infected MФs to present antigen to CD4 T cells (Fig. 5i).